Tardive dyskinesia: Probing abnormal metabolism with promethazine

Acta Psychiatrica Scandinavica

Volumn 99, Issue 4, 1999, Pages 294-299

  Bates, G D L ^a   Lopes, O ^b   Van Woerkom, A E ^b   Klovrza, L ^b   Waring, R ^b  

^a Gulson Road Clinic   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Metabolism; Movement disorder; Neuroleptic drug; Pharmacokinetics; Phenothiazine; Promethazine; Tardive dykinesia

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450; DRUG METABOLITE; NORPROMETHAZINE; PROMETHAZINE; PROMETHAZINE SULFOXIDE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; SCORING SYSTEM; TARDIVE DYSKINESIA;

EID: 0032951046     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1999.tb07228.x     Document Type: Article

References (23)

1. MORGENSTERN H, GLAZER WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Arch Gen Psychiatry 1993;50:723-733.
2. JESTE DV, RUSENBLATT JE, WAGNER RL et al. High serum neuroleptic levels in tardive dyskinesia? N Engl J Med 1979;301:1184.
3. JESTE DV, LINNOILA M, WAGNER RL, WYATT RJ. Serum neuroleptic concentrations and tardive dyskinesia. Psychopharmacology 1982;76:377-380.
4. MCCREADIE RG, ROBERTSON LJ, WILES DH. The Nithsdale Surveys. IX. Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiatry 1992;161:793-799.
5. WIDERLOV E, HAGGSTROM J-E, KILTS CD et al. Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia. Acta Psychiatr Scand 1982;66:294-305.
6. YESAVAGE JA, TANKE ED, SHEIKH JL. Tardive dyskinesia and steady-state serum levels of thiothixene. Arch Gen Psychiatry 1987;44:913-915.
7. ARMSTRONG M, DALY AK, BLENNERHASSETT R et al. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997;170:23-26.
8. ARTHUR H, DAHL ML, SIWERS B, SJOQVIST F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacology 1995;15:211-216.
9. BAZIRE S. Psychotropic drug directory 1995. The professionals' pocket handbook and aide memoir. Lancaster: Quay Publishing, 1995.
10. SCHOOLER NR, KANE JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.
11. GUY W. ECDEU assessment manual for psychopharmacology. Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare, 1976:218-222.
12. TAYLOR G, HOUSTON JB. Simultaneous determination of promethazine and two of its circulating metabolites by high-performance liquid chromatography. J Chromatography 1982;230:194-198.
13. SOCHOR J, KLIMES J, SRUMOVA M. High-performance liquid chromatographic determination of terguride in solid dosage forms and plasma. J Chromatography B: Biomed Appl 1995;663:309-313.
14. BERTILSON L, DAHL M-L, SJOQVIST F et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993;341:63.
15. JESTE DV, DELISI LE, ZALCMAN S et al. A biochemical study of tardive dyskinesia in young male patients. Psychiatr Res 1981;4:327-331.
16. 3H] GBR12935 binding proteins. Arch Biochem Biophysics 1990;276:424-434.
17. COHEN G. Oxyradical toxicity in catecholamine neurones. Neurotoxicology 1984;5:77-82.
18. PARK BE, NETSKY MG, BETILL WL. Pathogenesis of pigment and spheroid formation in Hallervorden-Spatz syndrome and related disorders. Neurology 1975;25:1172-1178.
19. CADET JL, LOHR JB, JESTE DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107-108.
20. SOARES K, MCGRATH J, ADAMS C. Evidence and tardive dyskinesia. Lancet 1996;347:1696-1697.
21. PAOLINI M, LEGATOR MS. Healthy broccoli? Nature 1992;357:448.
22. MEYER JW, WOGGON B, BAUMANN P et al. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacology 1989;39:613-614.
23. SPINA E, STURIALE V, VALVO S et al. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. Acta Psychiatr Scand 1992;86:364-366.